Endocrine Abstracts

JOINT2243

Introduction: Gonadotropin-releasing hormone (GnRH) analogs, such as Leuprolide acetate (LA), are the standard treatment for central precocious puberty (CPP). The 1-month formulation of LA is widely used; however, comparative data on the effectiveness of the 11.25 mg three-monthly formulation remain limited. This study aimed to evaluate the efficacy of 3.75 mg monthly and 11.25 mg three-monthly LA in achieving pubertal suppression in girls with CPP.

Methods: A total of 136 girls with CPP were included in the study. Eighty-six patients were treated with LA 3.75 mg monthly, and fifty patients received LA 11.25 mg every three months for one year. Anthropometric, laboratory, and radiological measurements were compared at the beginning and the end of the treatment period. Pubertal suppression was defined as a luteinizing hormone (LH) level below 4 IU/lat 90 minutes after GnRH analog administration.

Results: Baseline demographic and clinical characteristics did not differ between the groups. The mean age of all patients at baseline was 8.3 ± 0.7 years. The mean age was 8.4 ± 0.8 years in the 3.75 mg group and 8.2 ± 1 years in the 11.25 mg group, with no significant difference between the groups (p: 0.210). After 12 months of treatment, there were no significant differences between the two groups in terms of bone age- chronological age difference, height standard deviation score (SDS), body mass index SDS, or uterine volume. Pubertal suppression was achieved in 72.1% of patients in the 3.75 mg group and 78% in the 11.25 mg group (P = 0.291). Post-treatment LH levels were comparable between the two groups (3.75 mg: 2.2 ± 2 IU/l, 11.25 mg: 2.3 ± 1.6 IU/l, P = 0.894).

Conclusions: The 11.25 mg three-month depot of LA demonstrated comparable efficacy to the 3.75 mg monthly depot in terms of pubertal suppression, and hormonal control. Both regimes showed effective suppression of puberty. However, the 11.25 mg three-month formulation may offer improved patient compliance due to the less frequent dosing schedule, making it a more convenient treatment option while maintaining similar safety and efficacy in managing CPP.